Validation of a suspicion index to identify patients at risk for hereditary angioedema
- PMID: 37780104
- PMCID: PMC10509908
- DOI: 10.1016/j.jacig.2022.08.009
Validation of a suspicion index to identify patients at risk for hereditary angioedema
Abstract
Background: Hereditary angioedema (HAE) is a genetic condition characterized by dysregulation of the contact (kallikrein-bradykinin) pathway, leading to recurrent episodes of angioedema.
Objective: This project sought to determine whether a suspicion index screening tool using electronic health record (EHR) data can identify patients with an increased likelihood of a diagnosis of HAE.
Methods: A suspicion index screening tool for HAE was created and validated by using known patients with HAE from the medical literature as well as positive and negative controls from HAE-focused centers. Through the use of key features of medical and family history, a series of logistic regression models for 5 known genetic causes of HAE were created. Top variables populated the digital suspicion scoring system and were run against deidentified EHR data. Patients at 2 diverse sites were categorized as being at increased, possible, or no increased risk of HAE.
Results: Prediction scoring using the strongest 13 variables on the "real-world" EHR-positive control data identified all but 1 patient with C1 inhibitor deficiency and patient with non-C1 inhibitor deficiency without false-positive results. The 2 missed patients had no documented family history of HAE in their EHR. When the prediction scoring variables were expanded to 25, the screening algorithm approached 100% sensitivity and specificity. The 25-variable algorithm run on general population EHR data identified 26 patients at the medical centers as being at increased risk for HAE.
Conclusions: These results suggest that development, validation, and implementation of suspicion index screening tools can be useful to aid providers in identifying patients with rare genetic conditions.
Keywords: Hereditary angioedema; angioedema; electronic health record; genetics; suspicion index screening tool.
© 2022 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.
Figures
References
-
- Busse P.J., Christiansen S.C., Riedl M.A., Banerji A., Bernstein J.A., Castaldo A.J., et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9:132–150.e3. - PubMed
-
- Zanichelli A., Longhurst H.J., Maurer M., Bouillet L., Aberer W., Fabien V., et al. Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting. Ann Allergy Asthma Immunol. 2016;117:394–398. - PubMed
-
- Liu S., Wang X., Xu Y., Xu Q., Zhi Y. Risk factors for diagnostic delay in Chinese patients with hereditary angioedema. Allergy Asthma Proc. 2019;40:343–349. - PubMed
-
- Hastie T., Tibshirani R., Friedman J.S. 2nd ed. Springer-Verlag; New York: 2009. The elements of statistical learning.
